It saves lives and slows the progression of AIDS, study confirms
WEDNESDAY, Nov. 19 (HealthDay News) -- A new study finalizes research that changed guidelines around the world regarding when HIV-infected babies should begin drug therapy.
Based on preliminary findings released last year, several health agencies like the World Health Organization now advise doctors to begin HIV treatment early in babies, instead of waiting because of fear that the medications will do more harm than good.
"Given good health care, these babies can survive and grow up to become parents themselves," said study lead author Avy Violari, who directs pediatric clinical research at the University of Witwatersrand's Perinatal HIV Research Unit in Johannesburg, South Africa.
HIV, the virus that causes AIDS, remains a major health problem for babies worldwide, with an estimated 500,000 HIV-infected infants born in 2006.
In 2007, researchers assigned 377 HIV-positive infants in South Africa to one of three different HIV treatments. The babies, aged 6 to 12 weeks, began either immediate drug therapy for 40 or 96 weeks, or weren't given medication until symptoms appeared.
The researchers stopped the trial in 2007, because survival rates were greatly improved among those children who received early treatment. Infant mortality was reduced by 76 percent, and HIV progression by 75 percent, the study said.
Death rates among those who got early treatment were similar to those among infants who weren't HIV-infected, said study co-author Dr. Diana Gibb, a professor of epidemiology at the MRC Clinical Trials Unit in London.
After the trial was stopped, those babies assigned to receive delayed treatment got early treatment instead.
The initial findings were released in July 2007. The study confirming those findings was published in the Nov. 20 issue of the New England Journal of Medicine.
All rights reserved